News | April 19, 2007

New Contrast Agent, Imaging Technique Developed for Breast Cancer Diagnosis

April 20, 2007 - Researchers at the Harvard Medical School have developed a new technique that uses harmless light instead of X-ray imaging combined with a contrast agent that targets and highlights malignant micro-calcifications in the breast, while disregarding similar micro-calcifications found in benign breast conditions.

When used with a non-invasive imaging that uses harmless light instead of x-rays, researchers have found that the contrast agent could help clinicians diagnose disease within minutes and determine where biopsies are needed.

“Because this agent is highly selective in targeting the product of malignant tumors, this approach may prove most useful for monitoring women who have dense breast tissue or those who are at a higher-than-average risk for developing a malignant breast tumor,” said Dr. John Frangioni, M.D., Ph.D., associate professor of medicine and radiology, Harvard Medical School.

The new technique was presented at the 233rd national meeting of the American Chemical Society, the world’s largest scientific society held in Chicago, IL, USA in March 2007, by Harvard’s Kumar R. Bhushan, Ph.D., who led the chemistry group that participated in the study.

Related Content

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Contrast Media | August 15, 2017
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast...
Contrast Media from Bayer, trends in contrast media and developments in contrast media
Feature | Contrast Media | July 28, 2017 | By Dave Fornell
Here are several updates in medical imaging ...
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
July 18, 2017 — Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabri
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
FDA says gadolinium retention in the brain is not a safety issue
Feature | Magnetic Resonance Imaging (MRI) | May 25, 2017
A U.S. Food and Drug Administration (FDA) review of the safety ramifications of gadolinium-based contrast agents for...
Targeted MRI Could Pinpoint Aggressive Prostate Cancers Before They Spread

The ZD2-Gd probe, represented by the orange ball and green arrow, binds to the EDB-FN in the prostate cancer cells with high metastatic potential. This results in a strong MRI signal (upper right). Prostate cancer cells with low metastatic potential have no EDB-FN and so there is no MRI signal (lower right). Credit: Han, et al., Bioconjug Chem-Apr-2017

News | Prostate Cancer | May 24, 2017
A research team funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) has engineered a...
Scientists Develop Novel Chemical Dye to Improve MRI Liver Cancer Imaging
News | Magnetic Resonance Imaging (MRI) | May 03, 2017
May 3, 2017 — Scientists from the National University of Singapore (NUS) have developed a novel nanodiamond-based ...
Sponsored Content | Case Study | Contrast Media Injectors | April 13, 2017
The volume of computed tomography (CT) imaging exams continues to grow in the United States,[2] adding pressure to...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Overlay Init